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The oestrogen signal has long been implicated in the
oncogenesis and progression of breast cancers. The bi-
ological eﬀects of oestrogens are mediated through at
least two oestrogen receptors, ER’s a and b, which be-
long to the superfamily of nuclear hormone receptors.
The traditional prognostic assays, as well as the recently
developed cDNA array techniques, have demonstrated
that ERa is a biomarker predicting favourable disease
outcome and treatment response. However, data now
suggest that the dysregulation of ERa coregulators, as
well as the presence of an oestrogen hypersensitive
K303R ERa mutation [1] are also important in breast
tumour progression. Thus, dysregulation of components
of ERa signalling could serve as prognostic markers
associated with a worse prognosis later in the disease
process.
The identiﬁcation of ERb in 1996 raised the ques-
tion as to its role in breast cancer progression. The
DNA-binding domain of ERb is almost identical to
that of ERa, and ERb exhibits extensive regions of
similarity to ERa in the ligand-binding domain Fur-
thermore, ERb is similarly activated by oestrogens
and inhibited by anti-oestrogens, such as tamoxifen.
Although studies show that ERb is indeed expressed
in most human breast tumours, its involvement in
breast cancer progression remains controversial. One
study suggested that expression of ERb is associated
with lymph node-positive and higher-grade tumours
[2], while others have shown that ERb expression is
associated with node-negative and lower-grade cancers
[3]. Thus, there is no current consensus regarding the
clinical value of ERb measurements in breast cancer.
To assess the role of ERb in breast cancer, we
therefore conducted an immunoblot analysis with an
ERb-speciﬁc antibody in 305 axillary node-positive
tumours with clinical follow-up. We found no signif-
icant associations between ERb expression and ERa,
progesterone receptor (PR), and other factors related
to clinical outcome, such as tumour grade, age, and
proliferation, or two biomarkers of tamoxifen resis-
tance, the growth factor receptor HER-2 and the ER
coactivator, AIB1. ERb expression was not a signiﬁ-
cant prognostic factor in untreated patients. However,
given the relationship between the two ERs, we also
analysed the predictive value of ERb in tamoxifen-
treated patients. We explored multivariate Cox re-
gression analysis of disease-free survival (DFS) and
overall survival (OS). Our analyses revealed that pa-
tients with lower ERb values were approximately 2
times more likely to relapse than patients with higher
ERb values, suggesting that ERb is an independent
predictive factor for DFS in tamoxifen-treated, node-
positive patients. Similar results were obtained for OS
in the treated group. These data suggest that breast
cancers expressing low levels of ERb may be resistant
to tamoxifen treatment.
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